Lamotrigine monotherapy in newly diagnosed epilepsy or recurrent epilepsy:A multi-center, open-label study

Epilepsy & Seizure ◽

10.3805/eands.7.55 ◽

2014 ◽

Vol 7 (1) ◽

pp. 55-65 ◽

Author(s):

Takamichi Yamamoto ◽

Seung Bong Hong ◽

Masahiro Shimizu ◽

Katsuaki Sato ◽

Yotaro Numachi

Keyword(s):

Newly Diagnosed ◽

Open Label Study ◽

Label Study ◽

Lamotrigine Monotherapy

Download Full-text

Effects of lamotrigine monotherapy in patients with newly diagnosed juvenile myoclonic epilepsy: An open-label study

Current Therapeutic Research ◽

10.1016/j.curtheres.2005.06.004 ◽

2005 ◽

Vol 66 (3) ◽

pp. 230-237 ◽

Author(s):

James R. Schimschock ◽

Anne E. Hammer ◽

Robert P. Kustra ◽

John A. Messenheimer

Keyword(s):

Juvenile Myoclonic Epilepsy ◽

Myoclonic Epilepsy ◽

Newly Diagnosed ◽

Open Label Study ◽

Label Study ◽

Lamotrigine Monotherapy

Download Full-text

Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: A multi-center, uncontrolled, open-label study

Brain and Development ◽

10.1016/j.braindev.2015.10.007 ◽

2016 ◽

Vol 38 (4) ◽

pp. 407-413 ◽

Author(s):

Sawa Yasumoto ◽

Masahiro Shimizu ◽

Katsuaki Sato ◽

Atsuyo Kurata ◽

Yotaro Numachi

Keyword(s):

Newly Diagnosed ◽

Open Label Study ◽

Label Study ◽

Absence Seizures ◽

Lamotrigine Monotherapy

Download Full-text

Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China

Annals of Hematology ◽

10.1007/s00277-018-3488-1 ◽

2018 ◽

Vol 98 (1) ◽

pp. 143-150 ◽

Author(s):

Yan Zhang ◽

Wei Zhang ◽

Jian Li ◽

Minghui Duan ◽

Bing Han ◽

...

Keyword(s):

T Cell ◽

Cell Lymphoma ◽

T Cell Lymphoma ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Center ◽

Peripheral T Cell Lymphoma ◽

Open Label Study ◽

Download Full-text

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

The Lancet Haematology ◽

10.1016/s2352-3026(20)30323-9 ◽

2020 ◽

Vol 7 (12) ◽

pp. e861-e873 ◽

Author(s):

Paola Tacchetti ◽

Lucia Pantani ◽

Francesca Patriarca ◽

Maria Teresa Petrucci ◽

Elena Zamagni ◽

...

Keyword(s):

Haematopoietic Stem Cell Transplantation ◽

Haematopoietic Stem Cell ◽

Newly Diagnosed ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Long Term Follow Up

Download Full-text

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

Neuro-Oncology ◽

10.1093/neuonc/noy148.073 ◽

2018 ◽

Vol 20 (suppl_6) ◽

pp. vi20-vi20

Author(s):

Daniela A Bota ◽

Santosh Kesari ◽

David Piccioni ◽

Dawit Aregawi ◽

Patrick Roth ◽

...

Keyword(s):

Malignant Glioma ◽

Phase 1 ◽

Newly Diagnosed ◽

Who Grade ◽

Open Label Study ◽

Download Full-text

ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.05.366 ◽

2020 ◽

Vol 159 ◽

pp. 221

Author(s):

C. Marth ◽

C. Vulsteke ◽

M.J.R. Rubio ◽

V. Makker ◽

E.I. Braicu ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Iii ◽

Newly Diagnosed ◽

Open Label Study ◽

Label Study ◽

Recurrent Endometrial Cancer

Download Full-text

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.09.001 ◽

2018 ◽

Vol 18 (1) ◽

pp. 58-64 ◽

Author(s):

Soham D. Puvvada ◽

José Guillen-Rodriguez ◽

Abhijeet Kumar ◽

Lora Inclán ◽

Kara Heard ◽

...

Keyword(s):

Phase 2 ◽

Newly Diagnosed ◽

Open Label Study ◽

Label Study ◽

Mantle Cell ◽

Indolent Lymphomas

Download Full-text

To Evalaute the Efficacy of Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes Mellitus Patients by Assesing the HBA1C Percentage Reduction as a Single Diagnostic Tool for Glycemic Control and its Incidence in Preventing Macrovascular Complications: A Prospective Open Label Study for a Period of 6 Months Duration

Indian Journal of Public Health Research & Development ◽

10.5958/0976-5506.2019.03739.2 ◽

2019 ◽

Vol 10 (11) ◽

pp. 1467

Author(s):

T. Manivel ◽

G. Jagan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Percentage Reduction ◽

Newly Diagnosed ◽

Open Label Study ◽

Label Study ◽

Metformin Monotherapy

Download Full-text

An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early Observations

Journal of Hepatology ◽

10.1016/s0168-8278(16)00033-7 ◽

2016 ◽

Vol 64 (2) ◽

pp. S145-S146

Author(s):

K.H. Weiss ◽

A. Ala ◽

F. Askari ◽

D. Bega ◽

J. Bronstein ◽

...

Keyword(s):

Wilson Disease ◽

Phase 2 ◽

Newly Diagnosed ◽

Open Label Study ◽

Label Study ◽

Download Full-text

19 EGFR mutation rate in TRANSCRIPT: A study to assess the incidence of EGFR mutations in UK NSCLC patients with newly diagnosed locally advanced or metastatic disease. A single arm, open label study

Lung Cancer ◽

10.1016/s0169-5002(14)70020-0 ◽

2014 ◽

Vol 83 ◽

pp. S8

Author(s):

C. Lewanski ◽

I. Hennig ◽

S. Tahir ◽

T. Benepal ◽

S. Skaria ◽

...

Keyword(s):

Mutation Rate ◽

Metastatic Disease ◽

Egfr Mutation ◽

Locally Advanced ◽

Egfr Mutations ◽

Newly Diagnosed ◽

Open Label Study ◽

Label Study ◽

Download Full-text